Chap13 Dokka


Published on

Molecular Biology of The Cell : Chapter 13 and related application in the medical field.

Published in: Technology, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Chap13 Dokka

  1. 1. Vesicular Transport Kartheek Kumar Dokka Chapter 13
  2. 2. Vesicular Transport
  3. 3. Budding and Fusion
  4. 4. Clathrin Coated Vesicles
  5. 5. Clathrin Coated Vesicles
  6. 7. SNARES!!
  7. 8. Nerve Cell
  8. 9. How they move!
  9. 10. The Bacteria! The Neurotoxin: Botulinum
  10. 11. Botulinum Alert!
  11. 12. <ul><li>Purified sub-unit A of the botulinum toxin. </li></ul><ul><li>Botox-A is a protease and is known for its property of cleaving the SNARE proteins. </li></ul><ul><li>Allergan targeted the neuro-muscular </li></ul><ul><li>junctions to treat “Strabismus” and </li></ul><ul><li>“ Blepharospasm”. </li></ul>
  12. 13. Effect of Botox <ul><li>Example of botulinum toxin treatment in a patient with essential blepharospasm. </li></ul>
  13. 14. $$$ for Allergan!
  14. 15. We are… <ul><li>Syntaxin Ltd. is a newly formed biotechnology company focusing on discovery and development of new medicines derived from bacterial toxins to treat chronic diseases. </li></ul><ul><li>Hypersecretion of mucus into the airways is an important contributor to morbidity and mortality in many patients with severe chronic lung diseases, such as chronic obstructive pulmonary disorder (COPD), asthma and cystic fibrosis. </li></ul><ul><li>Current treatments for COPD are palliative and do not halt disease progression, and there is no specific treatment for the mucus hypersecretion. </li></ul><ul><li>In patients with COPD, levels of the mucins are increased in the respiratory mucus. </li></ul><ul><li>One possibility for inhibiting mucus secretion is to utilize the anti-secretory activity of proteases of clostridial neurotoxins, targeted to the mucin secreting cells of the airway using Syntaxin's novel recombinant proteins. </li></ul>
  15. 16. What did we do… <ul><li>Syntaxin explored a number of peptide ligands to receptors known to be present on mucin secreting cells of the respiratory epithelium, and proteases from serotypes of botulinum neurotoxin known to cleave SNARE proteins found within these cells. </li></ul><ul><li>The target product profile for this programme is a recombinant therapeutic protein that can be administered on an infrequent basis by inhalation to patients with a mucus hypersecretory component to their chronic respiratory condition such as COPD. </li></ul><ul><li>Targeted: A549 cells which are carcinomic human alveolar basal epithelial cells. [Cause excessive production of Mucus!] </li></ul><ul><li>With: R ecombinant therapeutic protein “SXN 187” [Recombinaint A-subunit of BoTox.] </li></ul>
  16. 17. What we got… <ul><li>Effect of SXN187 on intracellular mucin in A549 cells: </li></ul><ul><li>The level of mucus created by these cells is reduced and mucin was retained inside the treated cells . </li></ul><ul><li>C-Control: Must be Known Mucin Secretion Inhibitor. </li></ul><ul><li>EC-Experimental Control </li></ul>Through this biotech research & development model Syntaxin aims to develop a family of medicines for chronic disorders where cell secretion is a major contributor to their pathology.
  17. 18. So basically….. <ul><li>Chronic diseases involving neurotransmitter release can be treated using botulinum neurotoxins and in the future novel proteins to inhibit the neuron cells. </li></ul><ul><li>The overall status of various products by different companies using this technology in various pathologies: </li></ul>
  18. 19. References! <ul><li> </li></ul><ul><li> /.../ clathrin_pits.htm </li></ul><ul><li> </li></ul><ul><li> </li></ul><ul><li> </li></ul><ul><li> </li></ul><ul><li> </li></ul><ul><li>http:// </li></ul><ul><li> </li></ul><ul><li>http:// </li></ul><ul><li> </li></ul><ul><li> / [my favorite] </li></ul>